Scarica l'app Stockscreener
4.11
3.29%
-0.14
Dopo l'orario di chiusura:
4.28
0.17
+4.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.25
Aprire:
$4.25
Volume 24 ore:
3.59M
Relative Volume:
2.08
Capitalizzazione di mercato:
$670.13M
Reddito:
$823.60M
Utile/perdita netta:
$-116.00M
Rapporto P/E:
-3.1615
EPS:
-1.3
Flusso di cassa netto:
$-107.30M
1 W Prestazione:
-43.47%
1M Prestazione:
-48.62%
6M Prestazione:
-73.95%
1 anno Prestazione:
-83.51%
Intervallo 1D:
$4.075
$4.31
Intervallo di 1 settimana:
$3.83
$5.82
Portata 52W:
$3.83
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Nome
Myriad Genetics Inc
Settore
Industria
Telefono
801-584-3600
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Confronta MYGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.11 | 670.13M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
428.95 | 159.40B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.61 | 136.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
509.13 | 38.21B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.42 | 30.90B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.68 | 25.29B | 15.50B | 1.33B | 2.16B | 7.34 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Iniziato | Craig Hallum | Buy |
| 2024-12-10 | Iniziato | UBS | Neutral |
| 2024-12-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Underperform |
| 2024-05-08 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Ripresa | Piper Sandler | Neutral |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Underweight |
| 2023-05-23 | Aggiornamento | Goldman | Sell → Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Iniziato | Stephens | Equal-Weight |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Sell |
| 2019-09-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Downgrade | Needham | Strong Buy → Hold |
| 2019-07-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-03-12 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Needham | Strong Buy |
| 2018-11-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Iniziato | Goldman | Sell |
| 2018-01-22 | Reiterato | Barclays | Equal Weight |
| 2018-01-05 | Iniziato | BTIG Research | Buy |
| 2017-10-02 | Ripresa | Leerink Partners | Mkt Perform |
| 2017-08-09 | Reiterato | Barclays | Equal Weight |
| 2017-02-08 | Aggiornamento | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Iniziato | Deutsche Bank | Sell |
| 2016-10-10 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Mostra tutto
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Price T Rowe Associates Inc. MD Cuts Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Myriad genetics lowers 2025 revenue guidance by $35M amid GeneSight challenges - MSN
Robust Growth in Preventive Healthcare Technologies - openPR.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2025 Earnings Call Transcript - MSN
Myriad Genetics (NASDAQ:MYGN) Cut to “Equal Weight” at Wells Fargo & Company - Defense World
StockNews.com Downgrades Myriad Genetics (NASDAQ:MYGN) to Hold - Defense World
Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop - simplywall.st
Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential - Insider Monkey
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - Benzinga
Myriad Genetics Shares Drop After Downgrade From Wolfe Research - marketscreener.com
Global Consumer Genomics Market Set to Witness Significant - openPR.com
Myriad Genetics (MYGN) Downgraded as Price Target Significantly Lowered | MYGN Stock News - GuruFocus
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround - Yahoo Finance
Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullish - Investing.com India
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz | FinancialContent - FinancialContent
What Analysts Are Saying About Myriad Genetics Stock - Benzinga
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology - GlobeNewswire
Why Myriad Genetics (MYGN) Stock Is Down Today - Yahoo Finance
Goldman Sachs Adjusts Price Target for MYGN, Maintains Buy Rating | MYGN Stock News - GuruFocus
Raymond James Reiterates 'Outperform' But Lowers Price Target for MYGN | MYGN Stock News - GuruFocus
Future-Proofing Growth of Direct-to-consumer Genetic Health - openPR.com
Myriad Genetics (MYGN) Target Price Reduced by Analyst Amid Challenges | MYGN Stock News - GuruFocus
UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating - marketscreener.com
Earnings call transcript: Myriad Genetics Q1 2025 Misses Revenue Expectations By Investing.com - Investing.com South Africa
UBS Adjusts Price Target for Myriad Genetics (MYGN) Following Q1 Results | MYGN Stock News - GuruFocus
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook - Yahoo Finance
Raymond James Adjusts Price Target for Myriad Genetics (MYGN) | MYGN Stock News - GuruFocus
Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22 - marketscreener.com
Myriad Genetics (MYGN) Faces Downgrade Amid Growth Concerns | MY - GuruFocus
Myriad Genetics (MYGN) Faces Downgrade Amid Growth Concerns | MYGN Stock News - GuruFocus
Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
Myriad Genetics Reports Mixed Q1 2025 Results - TipRanks
Myriad Genetics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics Q1 2025 Earnings Call Transcript - MarketBeat
Myriad: Q1 Earnings Snapshot - MySA
Earnings call transcript: Myriad Genetics Q1 2025 Misses Revenue Expectations - Investing.com Nigeria
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Myriad Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5% - Yahoo Finance
Myriad Genetics Inc Reports Q1 2025 Earnings: EPS of $(0.03) Bea - GuruFocus
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Myriad Genetics Q1 2025 slides: Revenue declines 3% as company slashes guidance - Investing.com
Myriad Genetics (MYGN) Lowers 2025 Guidance Following Revenue Miss | MYGN Stock News - GuruFocus
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance - The Manila Times
Myriad Genetics Reports 3% Decline in Q1 2025 Revenue; Updates Financial Guidance for Full-Year - Nasdaq
Earnings Flash (MYGN) Myriad Genetics Posts Q1 Adjusted EPS $-0.03, vs. FactSet Est of $-0.05 - marketscreener.com
Myriad Genetics Q1 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
PARP Inhibitor Biomarkers Market Top PlayersMyriad Genetics, - openPR.com
Myriad Genetics Quarterly Earnings Preview: What to ExpectNews and Statistics - IndexBox
What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings - Yahoo Finance
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help - Hometown Stations
Myriad Genetics Inc Azioni (MYGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):